title: Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice.
abstract: OBJECTIVE
  To assess the effectiveness of the golimumab (GLM) 50-mg and 100-mg regimens in patients with rheumatoid arthritis (RA) in daily practice.
  
  
  METHODS
  We retrospectively analyzed RA patients who started GLM between September 2011 and July 2012. Patients were divided into three groups: a 50-mg group; a 50/100-mg group (had a dose increase to 100 mg); and a 100-mg group (started GLM at 100 mg). We assessed Disease Activity Score 28 (DAS28) and treatment continuation rate. Risk factors associated with time to discontinuation of the 50-mg regimen were determined with proportional hazards analysis.
  
  
  RESULTS
  We analyzed 74 patients: 43 in the 50-mg group, 23 in the 50/100-mg group, and 8 in the 100-mg group. DAS28 improved from 4.0 ± 1.0, 4.8 ± 1.0, and 4.7 ± 1.9, respectively, at baseline to 2.4 ± 1.2, 3.3 ± 1.5, and 2.5 ± 0.7, respectively, at week 52. Treatment continuation rates at week 52 were 73.7%, 60.9%, and 87.5%, respectively. In the 50/100-mg group, the mean DAS28 improved significantly from 4.4 ± 1.2 before to 3.6 ± 1.3 12 weeks after the dose increase. Oral corticosteroid therapy ≥ 5 mg/day, previous use of two biologic agents, and DAS28 > 5.1 at initiation of GLM were significantly associated with discontinuation of the 50-mg regimen.
  
  
  CONCLUSIONS
  Both GLM 50-mg and 100-mg regimens are effective in patients with RA in daily practice.
authors.affiliation: Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan.
authors.forename: Eri
authors.initials: E
authors.lastname: Sato
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.forename: Ayako
authors.initials: A
authors.lastname: Nakajima
authors.forename: Eisuke
authors.initials: E
authors.lastname: Inoue
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shimizu
authors.forename: Rei
authors.initials: R
authors.lastname: Yamaguchi
authors.forename: Moeko
authors.initials: M
authors.lastname: Ochiai
authors.forename: Kumi
authors.initials: K
authors.lastname: Shidara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Hoshi
authors.forename: Naoki
authors.initials: N
authors.lastname: Sugimoto
authors.forename: Yohei
authors.initials: Y
authors.lastname: Seto
authors.forename: Atsuo
authors.initials: A
authors.lastname: Taniguchi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Momohara
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; C529000:golimumab
keywords: Biologic DMARD; Disease activity score 28; Golimumab; Rheumatoid arthritis